Portable CRISPR-based diagnostic tool detects mpox in Sierra Leone field tests, according to a report by the World Health Organization (WHO) on June 5, 2026. The tool, developed by a collaboration of global health institutions, demonstrated 98% accuracy in rapid mpox detection during trials in Freetown. The initiative aims to enhance outbreak response in regions with limited laboratory infrastructure.
Field Testing and Technical Innovation
The diagnostic device, leveraging CRISPR-Cas12 technology, was deployed in Sierra Leone’s Western Area in May 2026 as part of a pilot program. Unlike traditional PCR tests, which require centralized labs, the tool enables on-site analysis within 30 minutes using a portable cartridge system. WHO officials highlighted its potential to reduce diagnostic delays, particularly in rural areas where access to medical facilities is constrained.
Collaborative Development and Deployment
The project involved partnerships between the WHO, the African Union’s African Centres for Disease Control and Prevention (Africa CDC), and biotech firms including Mammoth Biosciences and OXGENE. A WHO statement noted that the tool’s design prioritizes ease of use, requiring minimal training for healthcare workers. Field trials in Sierra Leone included 200 participants, with results validated against gold-standard sequencing methods.
Public Health Implications
Mpox outbreaks in West Africa have historically been challenging to contain due to fragmented surveillance systems. The portable diagnostic tool addresses this gap by providing real-time data, enabling quicker isolation of cases and contact tracing. Dr. Amina Juma, head of the Africa CDC’s infectious diseases division, emphasized that the technology could “transform outbreak management” if scaled nationally.
Challenges and Next Steps
While the trials showed promise, concerns remain about manufacturing capacity and distribution logistics. The WHO plans to expand testing to Guinea and Liberia by late 2026, pending regulatory approvals. Critics, including some local health advocates, have called for transparency in cost structures and community engagement to ensure equitable access.
Future Prospects
The success of the Sierra Leone trials could influence global health policies on point-of-care diagnostics. The WHO has requested additional funding to support large-scale production, with a focus on low-resource settings. If approved, the tool may be integrated into broader initiatives to combat emerging infectious diseases, including variants of mpox and other viral threats.
